Metastatic Breast Cancer Hr Her2 clinical trials

Explore recruiting metastatic breast cancer hr her2 clinical trials.

Recruiting metastatic breast cancer hr her2 studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Breast Cancer Hr Her2 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

SAFIR 03 - LibHERty: A ctDNA screening program in patients with HR+, HER2 low metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor followed by a single arm phase II trial of trastuzumab-deruxtecan in patients with persistent ctDNA after 1 month of treatment with endocrine therapy combined with CDK4/6 inhibitor

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Breast Cancer Hr Her2 trials by city

Metastatic Breast Cancer Hr Her2 clinical trials

Recruiting metastatic breast cancer hr her2 studies right now

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Also recruiting in Europe

Metastatic Breast Cancer Hr Her2 trials by city

Other conditions